Ribupatide
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
Fujian Shengdi Pharmaceutical Co · Phase 2 · Active, not recruiting · Enrollment 264
No selected arm has a reported week for this endpoint.
A solid line connects the weeks the source reports.